All In Biotech

NDA 205739 · Vifor Pharma

Veltassa

Patiromer Sorbitex Calcium · Oral · Potassium Binder

Novel

Last checked: Nov 20, 2026Latest source record: Oct 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 21, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

13,806

6,761 serious, 2,126 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 31, 2025.

Veltassa is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] . Veltassa is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. ( 1 ) Limitation of Use Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 )

Mechanism: Veltassa is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol counterion. Veltassa increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 2023 Supplement 38 · Efficacy Label
  • May 2, 2018 Supplement 16 · Efficacy LetterLabel
  • Oct 21, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
4 products under this application
  • VELTASSA · PATIROMER SORBITEX CALCIUM EQ 25.2GM BASE/PACKET · POWDER, ORAL · Discontinued
  • VELTASSA · PATIROMER SORBITEX CALCIUM EQ 8.4GM BASE/PACKET · POWDER, ORAL · Prescription
  • VELTASSA · PATIROMER SORBITEX CALCIUM EQ 1GM BASE/PACKET · POWDER, ORAL · Prescription
  • VELTASSA · PATIROMER SORBITEX CALCIUM EQ 16.8GM BASE/PACKET · POWDER, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Patiromer Sorbitex" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • constipation2,146
  • death1,832
  • diarrhoea1,296
  • hospitalisation980
  • off label use941
  • blood potassium increased802
  • nausea713
  • drug dose omission672
  • malaise584
  • abdominal discomfort541
  • inappropriate schedule of drug administration461
  • vomiting450

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20163,462
20174,594
20181,774
20191,327
2020896
2021569
2022313
2023192
2024191
2025318
2026170

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Veltassa (Patiromer Calcium Sorbitex)

2024 spending

$175M

Beneficiaries

52,133

163,389 claims

Per beneficiary

$3,358

$34.14 per unit

View as table
YearSpending
2020$111,516,027
2021$105,568,566
2022$110,617,058
2023$153,775,939
2024$175,068,084

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Vifor Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.